Waterfront Wealth Inc. Buys 60,798 Shares of Amarin Corporation PLC $AMRN

Waterfront Wealth Inc. lifted its position in Amarin Corporation PLC (NASDAQ:AMRN) by 42.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 203,338 shares of the biopharmaceutical company’s stock after buying an additional 60,798 shares during the quarter. Waterfront Wealth Inc. owned approximately 0.98% of Amarin worth $2,940,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Jones Financial Companies Lllp grew its stake in Amarin by 449,522.1% during the first quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock valued at $815,000 after acquiring an additional 1,811,574 shares in the last quarter. Millennium Management LLC lifted its stake in Amarin by 192.6% in the 3rd quarter. Millennium Management LLC now owns 132,391 shares of the biopharmaceutical company’s stock worth $2,169,000 after purchasing an additional 87,147 shares in the last quarter. Jump Financial LLC purchased a new stake in Amarin in the 2nd quarter worth approximately $623,000. JPMorgan Chase & Co. boosted its holdings in Amarin by 534.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,754 shares of the biopharmaceutical company’s stock valued at $356,000 after purchasing an additional 18,324 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Amarin in the fourth quarter worth $239,000. 22.25% of the stock is currently owned by institutional investors.

Amarin Price Performance

Shares of Amarin stock opened at $15.12 on Friday. Amarin Corporation PLC has a 1 year low of $12.96 and a 1 year high of $20.90. The firm has a market cap of $317.07 million, a PE ratio of -23.26 and a beta of 0.80. The company has a 50 day simple moving average of $15.04 and a two-hundred day simple moving average of $14.86.

Analysts Set New Price Targets

AMRN has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a research report on Monday, April 20th. Zacks Research upgraded Amarin from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Amarin currently has a consensus rating of “Moderate Buy”.

Amarin Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.